| Literature DB >> 33658818 |
Lijuan Yang1, Weihui Yu1, Wei Pan1, Shuoping Chen1, Xiwen Ye1, Xuejiang Gu1, Xiang Hu1.
Abstract
PURPOSE: Prognostic nutritional index (PNI) is an effective tool to evaluate the nutritional conditions and predict prognosis, but clinical data are limited for the use of PNI in diabetic retinopathy (DR). This study aimed to investigate the relationship of PNI with the prevalence and severity of DR in patients with type 2 diabetes mellitus (T2DM). PATIENTS AND METHODS: This cross-sectional analysis enrolled 1023 individuals with T2DM hospitalized between 2017-2020. PNI was calculated as 10 × serum albumin (g/l) + 0.005 × total lymphocyte count (cells/mL). DR severity was categorized as no, nonproliferative, and vision-threatened DR (VTDR) according to the modified Airlie House classification. Multivariate-adjusted odds ratio (OR) with 95% confidence interval (CI) for the prevalent DR in the top (Q4) compared with the bottom quartile (Q1) of PNI levels were estimated by using logistic regression analyses.Entities:
Keywords: diabetic retinopathy; obesity; prognostic nutritional index; type 2 diabetes mellitus
Year: 2021 PMID: 33658818 PMCID: PMC7920509 DOI: 10.2147/DMSO.S295757
Source DB: PubMed Journal: Diabetes Metab Syndr Obes ISSN: 1178-7007 Impact factor: 3.168
Characteristics of Study Participants
| No DR | NPDR | VTDR | |
|---|---|---|---|
| N | 501 | 365 | 157 |
| Age(years) | 57.0(54.0–63.0) | 59.0(55.0–64.0)* | 59.0(54.5–64.5) |
| Female/Male | 199/302 | 152/213 | 68/69 |
| DM duration (months, 0–491) | 68.0(15.0–136.0) | 134.0(84.0–188.0)** | 153.0(85.0–237.0)** |
| Albumin(g/l) | 39.46±3.58 | 38.30±4.03** | 36.91±5.10**‡ |
| Lymphocyte count (cells/mL) | 2.02±0.66 | 1.94±0.63* | 1.78±0.61**† |
| PNI | 49.56±5.23 | 47.95±5.27** | 45.75±6.30**‡ |
| BMI(kg/m2) | 24.61±3.07 | 24.55±3.45 | 24.26±3.15 |
| DBP(mmHg) | 73.51±10.12 | 73.46±10.61 | 73.89±11.70 |
| SBP(mmHg) | 126.36±17.27 | 131.67±19.04** | 135.42±21.15**† |
| WC(cm, 62.0–121.0) | 88.0(82.0–95.0) | 89.0(84.0–95.0) | 88.5(83.0–94.9) |
| HbA1c(%, 5.0–17.5) | 9.20(7.65–11.20) | 9.40(8.20–11.00) | 9.55(8.00–11.40) |
| FPG(mmol/L, 3.9–23.7) | 7.00(5.70–8.80) | 7.30(5.80–9.45) | 8.05(5.70–10.28)* |
| Hb(g/L) | 139.44±13.81 | 135.20±16.22** | 127.33±18.43**‡ |
| RBC(cells/mL) | 4.58±0.45 | 4.47±0.54* | 4.28±0.67**‡ |
| WBC(cells/mL) | 6.59±1.77 | 6.61±1.76 | 6.86±2.11 |
| PLT(cells/mL) | 215.00±60.08 | 219.01±59.10 | 230.97±85.59* |
| Scr(umol/L, 30.0–347.0) | 62.0(53.0–73.0) | 62.0(51.0–76.0) | 63.0(50.0–81.0) |
| SUA(umol/L, 108.0–751.0) | 302.0(244.8–263.5) | 307.5(256.0–367.0) | 322.0(269.0–391.0)* |
| TG(mmol/L, 0.51–10.46) | 1.45(1.05–2.05) | 1.49(1.04–2.27) | 1.55(1.12–2.21) |
| LDL-c(mmol/L, 0.61–5.58) | 2.48(1.95–3.18) | 2.43(1.87–3.12) | 2.55(1.90–3.38) |
| HDL-c(mmol/L, 0.48–3.13) | 1.00(0.85–1.20) | 1.01(0.85–1.21) | 1.02(0.84–1.20) |
Notes: Data are the mean ± standard deviation, median (interquartile range), and n (%). *P < 0.05 versus No DR. **P < 0.001 versus No DR. †P < 0.05 versus NPDR. ‡P < 0.001 versus NPDR.
Abbreviations: DR, diabetic retinopathy; NPDR, nonproliferative diabetic retinopathy; VTDR, vision-threatening diabetic retinopathy; DM duration, diabetes mellitus duration; PNI, prognostic nutritional index; BMI, body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure; WC, waist circumference; HbA1c, glycated hemoglobin A1c; FBG, fasting blood glucose; Hb, hemoglobin; RBC, red blood cell; WBC, white blood cell; PLT, platelet; Scr, serum creatinine; SUA, serum uric acid; TG, triglyceride; LDL-c, low-density lipoprotein cholesterol; HDL-c, high-density lipoprotein cholesterol.
Figure 1The presence of diabetic retinopathy among PNI quartiles.
Figure 2(A) Interaction of the present and severity of diabetic retinopathy between PNI and BMI. (B) Interaction of the present and severity of diabetic retinopathy between PNI and WC.
Univariate and Multivariate Analyses of Factors Associated with DR in Patients with T2DM
| Variables | Univariate | Multivariate | ||
|---|---|---|---|---|
| Age(years) | 0.012 | 1.027(1.006–1.048) | 0.395 | 0.988(0.961–1.016) |
| Gender | 0.430 | 0.905(0.705–1.161) | 0.326 | 1.230(0.814–1.858) |
| DM duration(years) | <0.001 | 1.009(1.007–1.010) | <0.001 | 1.009(1.007–1.011) |
| PNI | <0.001 | 0.926(0.904–0.948) | <0.001 | 0.941(0.911–0.972) |
| BMI(kg/m2) | 0.473 | 0.986(0.949–1.025) | 0.071 | 0.932(0.864–1.006) |
| DBP(mmHg) | 0.907 | 1.001(0.989–1.012) | 0.900 | 1.001(0.981–1.002) |
| SBP(mmHg) | <0.001 | 1.019(1.012–1.026) | 0.001 | 1.109(1.008–1.031) |
| WC(cm) | 0.760 | 1.002(0.989–1.016) | 0.333 | 1.013(0.987–1.041) |
| HbA1c(%) | 0.221 | 1.035(0.980–1.093) | 0.005 | 1.113(1.033–1.199) |
| Hb(g/L) | <0.001 | 0.973(0.965–0.981) | 0.008 | 0.975(0.957–0.993) |
| RBC(cells/mL) | <0.001 | 0.536(0.418–0.687) | 0.566 | 1.159(0.700–1.919) |
| WBC(cells/mL) | 0.404 | 1.029(0.962–1.102) | 0.316 | 1.049(0.956–1.151) |
| PLT(cells/mL) | 0.061 | 1.002(1.000–1.004) | 0.319 | 1.001(0.999–1.004) |
| Scr (umol/L) | 0.002 | 1.009(1.003–1.015) | 0.294 | 1.005(0.996–1.014) |
| SUA(umol/L) | 0.120 | 1.001(1.000–1.003) | 0.374 | 1.001(0.999–1.003) |
| TG(mmol/L) | 0.218 | 1.065(0.963–1.178) | 0.040 | 1.154(1.006–1.323) |
| HDL-c(mmol/L) | 0.976 | 1.006(0.661–1.533) | 0.286 | 1.356(0.775–2.374) |
| LDL-c(mmol/L) | 0.645 | 0.968(0.844–1.110) | 0.998 | 1.000(0.838–1.194) |
Abbreviations: DR, diabetic retinopathy; DM duration, diabetes mellitus duration; PNI, prognostic nutritional index; BMI, body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure; WC, waist circumference; HbA1c, glycated hemoglobin A1c; Hb, hemoglobin; RBC, red blood cell; WBC, white blood cell; PLT, platelet; Scr, serum creatinine; SUA, serum uric acid; TG, triglyceride; LDL-c, low-density lipoprotein cholesterol; HDL-c, high-density lipoprotein cholesterol.